Browsing by Author "Colak, Dilsen"

Now showing 1 - 9 of 9

Combined Versus Sequential Antracycline and Taxane Adjuvant Regimens in Triple Negative Breast Cancer Patients.
(2016) Oguz, Arzu; Keskin, Gul Sema Yildiran; Akcali, Zafer; Colak, Dilsen; Altundag, Ozden; Altundag, Mustafa Kadri; https://orcid.org/0000-0001-6512-6534; https://orcid.org/0000-0003-2473-4431; https://orcid.org/0000-0003-0197-6622; https://orcid.org/0000-0003-0197-6622; W-8004-2019; U-7339-2017; GRY-5456-2022; W-9219-2019; W-9219-2019
Dosetaxel Induced Pericardial Effusion in Two Gastric Cancer Patients
(2016) Yazilitas, Dogan; Oguz, Arzu; Colak, Dilsen; Imamoglu, Goksen I.; 0000-0001-6512-6534; W-8004-2019
The Effect of Haematological Parameters on Overall Survival in Advanced Stage Non Small Cell Lung Cancer
(2014) Oguz, Arzu; Colak, Dilsen; Ersoy, Ugur; Imamoglu, Inanc G.; Altinbas, Mustafa; Unal, Dilek; Zararsiz, Gokmen
In this study, we aimed to evaluate the prognostic value of pretreatment blood count values, particularly WBC counts, in patients with advanced non-small cell lung cancer (NSCLC). The records of 186 patients with advanced stage (stage IIIB and IV) NSCLC were assessed retrospectively. Patients were divided into 3 subgroups according to WBC levels; <= 0000 /mm(3) as Group 1, >10000 and <= 15000/mm(3) as Group 2 and >15000/mm(3) as Group 3. Patient and tumor characteristics as well as outcomes in terms of overall survival (OS) were evaluated. Median OS was 13.3 months in the whole population, 25.7 months in stage IIIB and 8.9 months in stage IV patients. According to the pretreatment leukocyte values, median OS was 17.9 months in Group 1, 11.2 months in Group 2 and 8.4 months in Group 3 (p= 0.003). Median OS values in WBC groups according to stages IIIB and IV were significantly different (p< 0.001). In multivariate analyses, ECOG-PS 2 or 3, stage IV disease, anemia and high WBC levels were associated with poorer OS. In this study, higher pretreatment WBC levels were associated with poorer OS in patients with advanced stage NSCLC. Pretreatment WBC counts may represent a simple prognostic factor and may aid in tailoring treatment in patients with advanced NSCLC.
The impact of lymph node ratio on overall survival in patients with colorectal cancer
(2021) Imamoglu, Goksen İnanc; Oguz, Arzu; Cimen, Sanem; Eren, Tuelay; Karacin, Cengiz; Colak, Dilsen; Altsbas, Mustafa; Turker, Sema; Yazilita, Dogan; 34528566
Background: Lymph node metastasis is a predominant prognostic indicator in colorectal cancer. Number of lymph nodes removed surgically was demonstrated to correlate with staging accuracy and oncological outcomes. However, number of lymph nodes removed depends on uncontrolled variables. Therefore, a more reliable prognostic indicator is needed. Calculation of ratio of positive lymph nodes to total number of removed lymph nodes may be an appealing solution. Materials and Methods: We retrospectively analyzed data of 156 Stage III colorectal cancer patients whom underwent surgery between 2008 and 2015. Patients' demographic characteristics, tumor grade, location, vascular-perineural invasion status, number of removed lymph nodes, and ratio of positive lymph nodes to number of removed lymph nodes were recorded. Spearman correlation analysis was used to determine the correlation coefficient while Kaplan-Meier method and Cox proportional hazard regression model were performed for the prediction of survival and multivariate analysis, respectively. Results: Number of removed lymph nodes did not correlate with survival, but it was inversely correlated with number of positive lymph nodes. Multivariate analysis showed that ratio of removed positive lymph nodes to the total number of lymph nodes was a significant prognostic factor for survival for a ratio equal or above 0.31 was a poor prognostic indicator (108 months vs. 34 months, hazard ratio: 4.24 [95% confidence interval: 2.15-8.34]; P < 0.019). Tumor characteristics failed to demonstrate any prognostic value. Conclusions: This study showed that positive lymph node ratio (PLNR) is an important prognostic factor for Stage III colorectal cancer. Although 0.31 can be taken as threshold for "PLNR," prospective trials including larger patient groups are needed to validate its role as a prognostic indicator.
Investigational Tests and Treatments Performed in Terminal Stage Cancer Patients in Two Weeks Before Death: Turkish Oncology Group (TOG) Study
(2014) Turker, Ibrahim; Komurcu, Seref; Arican, Ali; Doruk, Hatice; Ozyilkan, Ozgur; Coskun, Hasan Senol; Colak, Dilsen; Cavusoglu, Emel Ucgul; Ata, Alper; Sezer, Ahmet; Cinkir, Havva Yesil; Senler, Filiz Cay; Arpaci, Fikret; https://orcid.org/0000-0001-8825-4918; https://orcid.org/0000-0002-6445-1439; 25412940; AAD-2817-2021; AAD-2667-2020
Although more palliative care is necessary for terminally ill cancer patients, excess investigational tests, invasive procedures, and treatments are given instead. Between November 2009 and December 2013, six hundred and twenty-four patients with end-stage cancer who were died at inpatient setting evaluated retrospectively. Patients' characteristics, sites of tumor and metastasis, tests and invasive procedures, treatments performed in the last 2 weeks before death were collected from the hospital files and analyzed. Median age of 624 patients was 58 (range 16-96) years. More than half of the patients (370, 59.3 %) were men. The most frequent cancer sites were gastrointestinal (GI) system (32.2 %), lung (24.0 %), and breast (11.1 %). Frequent metastatic sites were liver (34.8 %), bone (31.5 %), lung (23.3 %), and/or brain (16.9 %). Causes of death were respiratory failure, infections, and/or liver failure in 49.9, 23.9, and 19.4 % of patients, respectively. Radiological tests performed in the last 2 weeks before death were ultrasonography, computed tomography, magnetic resonance imaging, bone scan in 25.6, 16.3, 11.4, and 3.8 % of patients, respectively. Treatments received were intravenous (i.v) serum infusion, blood transfusion, total parenteral nutrition (TPN), human albumin infusion in 55.9, 44.1, 34.9, and 9.5 % of patients, respectively. Invasive procedures such as invasive pain relief, terminal sedation, and chemotherapy performed in 12.6, 4.4, and 10.0 % of patients, respectively. Central venous catheter application, paracentesis, thoracentesis, and GI endoscopy were applied in 41.7, 9.8, 5.6, and 3.4 % of the patients, respectively. Radiological tests, invasive procedures, TPN, and human albumin transfusion were used excessively in terminal stage cancer patients in our medical oncology inpatient clinics. Invasive pain relief and terminal sedation were still underused in our cancer clinics. There is an urgent need in developing national palliative care program to improve the understanding of end-of-life care in our medical oncology clinics.
Investigational Tests and Treatments Performed in Terminal-Stage Cancer Patients in Two Weeks Before Death: Supportive Care Study Group in Turkish Oncology Association
(2014) Turker, Ibrahim; Komurcu, Seref; Arican, Ali; Senier, Filiz Cay; Coskun, Hasan Senol; Colak, Dilsen; Ucgul, Emel; Ata, Alper; Sezer, Ahmet; Ozyilkan, Ozgur; Cinkir, Havva Yesli; Arpaci, Fikrot; https://orcid.org/0000-0001-8825-4918; AAD-2817-2021
Morphine: Patient Knowledge and Attitudes in the Central Anatolia Part of Turkey
(2014) Colak, Dilsen; Oguz, Arzu; Yazilitas, Dogan; Immamoglu, Inanc Goksen; Altinbas, Mustafa; 24998575
Background: In Muslim majority countries (MMC) opioid use for pain management is extremely low. The underlying factors contributing to this are not well defined. Aim: The aim of this study was to survey the attitudes of cancer patients towards morphine use for pain management in a MMC and identify the factors that influence patient decisions to accept or refuse morphine as treatment for cancer pain. Settings/participants: Patients were questioned whether they had pain or not, the severity and the medications for pain management. Questions included what type of medication they thought morphine was, whether or not they would be willing to take morphine if recommended for pain management and the basis for their decision if they were against morphine use. Results: Four hundred and eighty-eight patients participated in the study. Some 50% of the patients who refused morphine use and 36.8% of the patients who would prefer another drug, if possible, identified fear of addiction as the basis for their decision. Reservation of morphine for later in their disease was the case for 22.4% of the patients who refused morphine use. Only 13.7 % of the patients refusing morphine and 9.7% of the patients who preferred another drug, if possible, cited religious reasons as the basis for this decision. Conclusions: Identifying the underlying factors contributing to low opioid use for pain management in MMC is important. Once the underlying factors were identified, all efforts should be taken to overcome them as they are barriers to improving patient pain management.
Treatment of Lymph Node-Negative, Early-Stage HER2-Positive Breast Cancer
(2016) Oguz, Arzu; Keskin, Gul Sema; Colak, Dilsen; Altundag, Ozden; Akcali, Zafer; https://orcid.org/0000-0001-6512-6534; https://orcid.org/0000-0003-0197-6622; https://orcid.org/0000-0003-2473-4431; 26644534; W-8004-2019; GRY-5456-2022; GRY-5456-2022; W-9219-2019; U-7339-2017
Triple Negative Breast Cancer: Demographic and Clinicopathological Properties.
(2016) Keskin, Gul Sema Yildiran; Ogur, Arzu; Colak, Dilsen; Akcali, Zafer; Altundag, Ozden; Altundag, Mustafa Kadri; https://orcid.org/0000-0003-2473-4431; https://orcid.org/0000-0003-0197-6622; GRY-5456-2022; U-7339-2017; W-9219-2019